Community engagement with the Food and Drug Administration (FDA) is critical as potential therapies move through the pipeline toward regulatory consideration.
We are excited to share that FAST has been invited to speak at the FDA’s Center for Biologics Evaluation and Research (CBER) Office of Therapeutic Products (OTP) webinar on Thursday, October 5th!
The webinar, Warrior Families: Advancing Regenerative Medicine For Angelman Syndrome Through Science, will begin with a presentation by Dr. Allyson Berent, FAST’s chief science officer, and will be followed by a panel discussion with fellow rare disease advocates, sharing their experiences with advocacy and contributing to therapeutic product development for loved ones living with rare diseases.
Learn more about the webinar:
|